411 filings
8-K
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
PRE 14A
COCP
Cocrystal Pharma Inc
Preliminary proxy
26 Apr 24
5:12pm
10-K/A
2023 FY
COCP
Cocrystal Pharma Inc
Annual report (amended)
17 Apr 24
5:00pm
10-K
2023 FY
COCP
Cocrystal Pharma Inc
Annual report
28 Mar 24
8:01am
8-K
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
xbuhrund sow
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
mr89x
1 Mar 24
Termination of a Material Definitive Agreement
4:15pm
8-K
r0tlsj6nj1ggp
8 Jan 24
Regulation FD Disclosure
8:00am
8-K
k64tiw oeuuc
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
a7rg7hzasq2o1xu
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
gu2wl
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
xl4z4j25 m0uhqrp
4 Dec 23
Regulation FD Disclosure
8:00am
8-K
tm4ll6nzwc08t
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
a6tr5c z299
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
c2lhr
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
waep2k7
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
zqne6zq 9hlmnxbc79y
15 Jun 23
Other Events
4:57pm
424B5
zivn2 96d0uj1
15 Jun 23
Prospectus supplement for primary offering
4:54pm